NPCDR 2.0: the activity and structure landscape of natural product-based drug combination

Natural products (NPs) have emerged as the ideal candidates to combine with other therapeutic agents, and the NPCDR has been developed to provide the data on NP-based drug combinations. Recent study increasingly focuses on the exploration of the activity profiles and structural data of such combinations, which were regarded as the cornerstone for a deeper understanding of the therapeutic properties. Here, the NPCDR was thus updated to its 2.0 version by systematically offering the activity profiles and structural data of NP-based drug combinations. Particularly, a total of 3814 activity data were collected for 584 drug combinations, and the structure data of 123 natural products and clinical drugs that interacted with their therapeutic targets were provided, together with binding residues and energies. Moreover, various pharmacological data (such as ADMET properties, drug combination ratios, and interaction patterns between different targets) were provided for NP-based drug combinations. NPCDR 2.0 can now be freely accessed by all users at https://idrblab.org/npcdr/.

Authors

Institutions

Publication Details

Journal
Nucleic Acids Research
Published
2025-11-08
DOI
https://doi.org/10.1093/nar/gkaf1191
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NPCDR 2.0: the activity and structure landscape of natural product-based drug combination

Mengting Chen, Xinbing Sui, Feng Zhu, Zehua Liao et al.
Nucleic Acids Research
Computational Drug Discovery Methods
article

NPCDR 2.0: the activity and structure landscape of natural product-based drug combination

Mengting Chen, Xinbing Sui, Feng Zhu, Zehua Liao, Lihui Xu, Zhao Xiaohong, Xinyuan Yu, Ying Zhou, Zhiyu Zhu, Kaixuan Liu, Quan Gao
article en

Abstract

Natural products (NPs) have emerged as the ideal candidates to combine with other therapeutic agents, and the NPCDR has been developed to provide the data on NP-based drug combinations. Recent study increasingly focuses on the exploration of the activity profiles and structural data of such combinations, which were regarded as the cornerstone for a deeper understanding of the therapeutic properties. Here, the NPCDR was thus updated to its 2.0 version by systematically offering the activity profiles and structural data of NP-based drug combinations. Particularly, a total of 3814 activity data were collected for 584 drug combinations, and the structure data of 123 natural products and clinical drugs that interacted with their therapeutic targets were provided, together with binding residues and energies. Moreover, various pharmacological data (such as ADMET properties, drug combination ratios, and interaction patterns between different targets) were provided for NP-based drug combinations. NPCDR 2.0 can now be freely accessed by all users at https://idrblab.org/npcdr/.

Nucleic Acids ResearchVol. 54(D1)
Hangzhou Normal University (CN), Second Affiliated Hospital of Zhejiang University (CN), Zhejiang University (CN)
National Natural Science Foundation of China
Openalex Percentile: Top 65%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NPCDR 2.0: the activity and structure landscape of natural product-based drug combination — Mengting Chen, Xinbing Sui, et al. · Nucleic Acids Research (2025) | TGRS Research Map | TGRS